The role of hypoxiainducible factor 1 in tumor immune evasion

Simple item page
dc.contributor.authorYou, Lics
dc.contributor.authorWu, Wendacs
dc.contributor.authorWang, Xucs
dc.contributor.authorFang, Liurongcs
dc.contributor.authorAdam, Vojtěchcs
dc.contributor.authorNepovimová, Eugeniecs
dc.contributor.authorWu, Qinghuacs
dc.contributor.authorKuča, Kamilcs
dc.coverage.issue3cs
dc.coverage.volume41cs
dc.date.issued2021-05-12cs
dc.description.abstractHypoxia-inducible factor 1 (HIF-1) plays an indispensable role in the hypoxic tumor microenvironment. Hypoxia and HIF-1 are involved in multiple aspects of tumor progression, such as metastasis, angiogenesis, and immune evasion. In innate and adaptive immune systems, malignant tumor cells avoid their recognition and destruction by HIF-1. Tumor immune evasion allows cancer cells to proliferate and metastasize and is associated with immunotherapy failure and chemoresistance. In the hypoxic tumor microenvironment, HIF-1 signaling suppresses the innate and adaptive immune systems to evade immune attack by inducing the expression of immunosuppressive factors and immune checkpoint molecules, including vascular endothelial growth factor, prostaglandin E-2, and programmed death-ligand 1/programmed death-1. Moreover, HIF-1 blocks tumor-associated antigen presentation via major histocompatibility complex class I chain-related/natural killer group 2, member D signaling. Tumor-associated autophagy and the release of tumor-derived exosomes contribute to HIF-1-mediated immune evasion. This review focuses on recent findings on the potential mechanism(s) underlying the effect of hypoxia and HIF-1 signaling on tumor immune evasion in the hypoxic tumor microenvironment. The effects of HIF-1 on immune checkpoint molecules, immunosuppressive molecules, autophagy, and exosomes have been described. Additionally, the potential role of HIF-1 in the regulation of tumor-derived exosomes, as well as the roles of HIF-1 and exosomes in tumor evasion, are discussed. This study will contribute to our understanding of HIF-1-mediated tumor immune evasion, leading to the development of effective HIF-1-targeting drugs and immunotherapies.en
dc.formattextcs
dc.format.extent1622-1643cs
dc.format.mimetypeapplication/pdfcs
dc.identifier.citationMEDICINAL RESEARCH REVIEWS. 2021, vol. 41, issue 3, p. 1622-1643.en
dc.identifier.doi10.1002/med.21771cs
dc.identifier.issn0198-6325cs
dc.identifier.orcid0000-0002-8527-286Xcs
dc.identifier.other167779cs
dc.identifier.researcheridD-7686-2012cs
dc.identifier.urihttp://hdl.handle.net/11012/208401
dc.language.isoencs
dc.publisherWileycs
dc.relation.ispartofMEDICINAL RESEARCH REVIEWScs
dc.relation.urihttps://onlinelibrary.wiley.com/doi/10.1002/med.21771cs
dc.rights(C) Wileycs
dc.rights.accessopenAccesscs
dc.rights.sherpahttp://www.sherpa.ac.uk/romeo/issn/0198-6325/cs
dc.subjectexosomesen
dc.subjectHIF-1en
dc.subjecthypoxiaen
dc.subjectPD-L1en
dc.subjecttumor immune evasionen
dc.titleThe role of hypoxiainducible factor 1 in tumor immune evasionen
dc.type.driverarticleen
dc.type.statusPeer-revieweden
dc.type.versionacceptedVersionen
sync.item.dbidVAV-167779en
sync.item.dbtypeVAVen
sync.item.insts2025.02.03 15:50:14en
sync.item.modts2025.01.17 20:32:42en
thesis.grantorVysoké učení technické v Brně. Středoevropský technologický institut VUT. Chytré nanonástrojecs
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
You_2022_accepted.pdf
Size:
889.76 KB
Format:
Adobe Portable Document Format
Description:
You_2022_accepted.pdf
Download
Collections
Chytré nanonástroje